New hope for women with recurring gynecologic cancers: drug combo trial launches
NCT ID NCT07424664
First seen Feb 27, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study tests a combination of two drugs (becotatug vedotin and zimberelimab) in 30 women with cervical, vulvar, or vaginal cancer that has come back or spread. The goal is to see if the treatment can shrink tumors and control the disease. Participants will receive the drugs for up to one year, and the study will monitor safety and how long any benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE CERVICAL NEOPLASMS, RECURRENT; UTERINE CERVICAL NEOPLASMS, METASTATIC; VULVAR NEOPLASMS; VAGINAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.